Lyrus Life Sciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Lyrus Life Sciences Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $3.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Lyrus Life Sciences Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $3.7M Trade | TransData Nexus

Lyrus Life Sciences Private Limited

Indian Pharmaceutical Exporter · Antihistamines & Allergy Specialist · $3.7M Total Trade · DGFT Verified

Lyrus Life Sciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $3.7M across 2 products in 2 therapeutic categories. Based on 74 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Fexofenadine ($3.4M), Bisoprolol ($300.0K), .

Lyrus Life Sciences Private Limited — Export Portfolio & Destination Treemap

Lyrus Life Sciences Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Lyrus Life Sciences Private Limited? — Company Overview & Market Position

Lyrus Life Sciences Private Limited, incorporated on June 16, 2015, is a private unlisted pharmaceutical company based in Bangalore, Karnataka, India. The company is registered under the Corporate Identification Number (CIN) U24230KA2015PTC080902. As of the latest available data, Lyrus has an authorized share capital of ₹96.25 crore and a paid-up capital of ₹96.23 crore. The registered office is located at No.22, 7th Cross, Jaibharath Nagar, Bangalore, Karnataka 560033, India. The company specializes in the manufacture of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories.

What Does Lyrus Life Sciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Fexofenadine$3.4M 2Bisoprolol$300.0K

Lyrus Life Sciences Private Limited Therapeutic Categories — 2 Specializations

Product Portfolio — Top 2 by Export Value

Lyrus Life Sciences Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Fexofenadine	Antihistamines & Allergy	$3.4M	68	3.1%	8
2	Bisoprolol	Cardiovascular	$300.0K	6	0.4%	15

Lyrus Life Sciences Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $3.7M. The top category is Antihistamines & Allergy (91.9% of portfolio), followed by Cardiovascular (8.1%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Lyrus Life Sciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Lyrus Life Sciences operates state-of-the-art manufacturing facilities that adhere to current Good Manufacturing Practices (cGMP). These facilities are equipped with advanced technological solutions to support the development and commercialization of drug products in the global marketplace. The company's manufacturing capabilities encompass a range of dosage forms, including oral solids, liquids, dry powders for reconstitution, and dry powders in sachets, catering to both generic and specialty formulations.

3Key Leadership

The leadership team at Lyrus Life Sciences includes:

Hemanth Kumar Bothra: Managing Director, appointed on June 16, 2015.

Dasari Ramesh: Company Secretary, appointed on June 20, 2017.

Leela Kanwar: Director, appointed on June 16, 2015.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Lyrus Life Sciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Lyrus Life Sciences has established a commercial presence in key markets across Europe, Africa, Australia, the Middle East and North Africa (MENA) region, and Asia. The company focuses on developing and manufacturing pharmaceutical products that can add value to human health, with a balanced portfolio of ethical and complementary products. Lyrus offers services such as contract development and manufacturing of finished formulations, technology transfer, and R&D services.

2Emerging Markets

Lyrus Life Sciences has expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's focus on developing differentiated and innovative products positions it to address the unique healthcare needs of these regions. While specific details regarding WHO prequalification are not available, the company's commitment to quality and regulatory compliance suggests potential for access to these markets.

3Geographic Strategy

Lyrus Life Sciences demonstrates a diversified geographic strategy by establishing a presence in multiple international markets, including Europe, Africa, Australia, MENA, and Asia. This approach mitigates concentration risk and aligns with the company's strategic direction to become a trusted partner for innovative drug delivery solutions globally. The focus on both developed and emerging markets indicates a balanced approach to growth and market penetration.

Lyrus Life Sciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Lyrus Life Sciences' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's focus on developing and manufacturing pharmaceutical products suggests potential engagement with regulatory bodies, including the FDA, to ensure compliance and market access in the United States.

2WHO & EU GMP

While specific information regarding WHO prequalification and EU Good Manufacturing Practice (GMP) certificates for Lyrus Life Sciences is not available, the company's adherence to cGMP standards indicates a commitment to quality manufacturing practices. The company's focus on developing and manufacturing pharmaceutical products suggests potential engagement with regulatory bodies to ensure compliance and market access in various regions.

3CDSCO & Indian Regulatory

Lyrus Life Sciences holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory standards. The company's registered office is located in Bangalore, Karnataka, indicating adherence to state drug controller approvals. Specific details regarding export No Objection Certificates (NOCs) are not publicly available.

Lyrus Life Sciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Lyrus Life Sciences operates in a competitive pharmaceutical industry, with key competitors including Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., and Zydus Lifesciences Ltd. The company's focus on developing differentiated and innovative products, particularly in the neuropsychiatry and challenging delivery systems segments, positions it to address niche market needs and differentiate itself from competitors.

2Key Differentiators

Lyrus Life Sciences' key differentiators include its state-of-the-art R&D infrastructure, a team of qualified professionals with decades of industry experience, and a focus on developing differentiated and innovative products. The company's commitment to quality manufacturing practices and adherence to cGMP standards further enhance its competitive advantage.

3Strategic Position

Lyrus Life Sciences is strategically positioned as a research and technology-driven global specialty pharmaceutical company committed to developing differentiated and innovative products. The company's focus on formulation development, exhibit and commercial manufacturing, and a balanced portfolio of generic and specialty formulations aligns with its strategic direction to become a trusted partner for innovative drug delivery solutions globally.

Buyer Due Diligence Brief — Evaluating Lyrus Life Sciences Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Lyrus Life Sciences demonstrates a strong track record in the pharmaceutical industry, with a focus on developing and manufacturing high-quality finished pharmaceutical formulations. The company's adherence to cGMP standards and commitment to quality manufacturing practices indicate reliability and consistency in its export volumes. Specific details regarding export volume and consistency are not publicly available.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm the company's FDA facility registrations and approved ANDAs.

WHO-GMP Certification: Verify WHO prequalification status for relevant products.

EU GMP Certification: Ensure compliance with EU GMP standards.

Frequently Asked Questions — Lyrus Life Sciences Private Limited

How many pharmaceutical products does Lyrus Life Sciences Private Limited export from India?

Lyrus Life Sciences Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Fexofenadine ($3.4M), Bisoprolol ($300.0K). Total export value is $3.7M.

What is Lyrus Life Sciences Private Limited's total pharmaceutical export value?

Lyrus Life Sciences Private Limited's total pharmaceutical export value is $3.7M, based on 74 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Lyrus Life Sciences Private Limited cover?

Lyrus Life Sciences Private Limited exports across 2 therapeutic categories. The largest are Antihistamines & Allergy (91.9%, 1 products), Cardiovascular (8.1%, 1 products).

Get Full Lyrus Life Sciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.